Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

20105,450 citationsJournal Articlebronze Open Access

Authors

Philip W. Kantoff · Dana-Farber Cancer Institute

Celestia S. Higano · University of Washington

Neal D. Shore · Carolina Urologic Research Center

E. Roy Berger

Eric J. Small · University of California, San Francisco

David F. Penson · Vanderbilt University Medical Center

Charles H. Redfern · Sharp HealthCare Foundation

Abstract

The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; ClinicalTrials.gov number, NCT00065442.)

Topics & Keywords

Immunotherapy and Immune Responses Prostate Cancer Treatment and Research Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 5, pp. 411-422

DOI: 10.1056/nejmoa1001294

Field-Weighted Citation Impact: 153.83